Literature DB >> 12130708

Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.

Chitra D Mandyam1, Deepak R Thakker, Jennifer L Christensen, Kelly M Standifer.   

Abstract

Morphine tolerance in vivo is reduced following blockade of the orphanin FQ/nociceptin (OFQ/N)/opioid receptor-like 1 (ORL1) receptor system, suggesting that OFQ/N contributes to the development of morphine tolerance. We previously reported that a 60-min activation of ORL1 receptors natively expressed in BE(2)-C cells desensitized both mu and ORL1 receptor-mediated inhibition of cAMP. Investigating the mechanism(s) of OFQ/N-mediated mu and ORL1 receptor cross-talk, we found that pretreatment with the protein kinase C inhibitor, chelerythrine chloride (1 microM), blocked OFQ/N-mediated homologous desensitization of ORL1 and heterologous desensitization of mu opioid receptors. Furthermore, depletion of PKC by 12-O-tetradecanoylphorbol-13-acetate exposure (48 h, 1 microM) also prevented OFQ/N-mediated mu and ORL1 desensitization. OFQ/N pretreatment resulted in translocation of PKC-alpha, G protein-coupled receptor kinase 2 (GRK2) and GRK3 from the cytosol to the membrane, and this translocation was also blocked by chelerythrine. Reduction of GRK2 and GRK3 levels by antisense, but not sense DNA treatment blocks ORL1 and mu receptor desensitization. This suggests that PKC-alpha is required for GRK2 and GRK3 translocation to the membrane, where GRK can inactivate ORL1 and mu opioid receptors upon rechallenge with the appropriate agonist. Our results demonstrate for the first time the involvement of conventional PKC isozymes in OFQ/N-induced mu-ORL1 cross-talk, and represent a possible mechanism for OFQ/N-induced anti-opioid actions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130708     DOI: 10.1124/jpet.102.033159

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling.

Authors:  Bo Feng; Zhihua Li; Jia Bei Wang
Journal:  Mol Pharmacol       Date:  2011-01-06       Impact factor: 4.436

2.  Nociceptin/orphanin FQ receptor-driven heterologous desensitization of the major HIV-1 co-receptor CXCR4.

Authors:  David E Kaminsky; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2011-06-09       Impact factor: 4.147

3.  Orphanin FQ/nociceptin activates nuclear factor kappa B.

Authors:  Courtney L Donica; Vanessa I Ramirez; Hibah O Awwad; Nurulain T Zaveri; Lawrence Toll; Kelly M Standifer
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-06       Impact factor: 4.147

4.  Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Authors:  Anika Mann; Lionel Moulédous; Carine Froment; Patrick R O'Neill; Pooja Dasgupta; Thomas Günther; Gloria Brunori; Brigitte L Kieffer; Lawrence Toll; Michael R Bruchas; Nurulain T Zaveri; Stefan Schulz
Journal:  Sci Signal       Date:  2019-03-26       Impact factor: 8.192

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 6.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

7.  β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Authors:  Douglas G Tilley; Weizhong Zhu; Valerie D Myers; Larry A Barr; Erhe Gao; Xue Li; Jianliang Song; Rhonda L Carter; Catherine A Makarewich; Daohai Yu; Constantine D Troupes; Laurel A Grisanti; Ryan C Coleman; Walter J Koch; Steven R Houser; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690

8.  Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes.

Authors:  David E Kaminsky; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2007-09-15       Impact factor: 4.147

9.  Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.

Authors:  Manuela Di Benedetto; Chiara Cavina; Claudio D'Addario; Giorgia Leoni; Sanzio Candeletti; Brian M Cox; Patrizia Romualdi
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

10.  Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment.

Authors:  Yong Zhang; Courtney L Donica; Kelly M Standifer
Journal:  Neuropharmacology       Date:  2012-05-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.